Article Text

Download PDFPDF
Percutaneous valve-in-valve implantations: importance of knowing the effective internal diameter of bioprosthetic valves
  1. A B Gopalamurugan,
  2. Markus Reinthaler,
  3. Michael J Mullen
  1. Department for Structural Interventions, The Heart Hospital, University College London Hospitals NHS Trust, London, UK
  1. Correspondence to A B Gopalamurugan, Department for Structural Interventions, The Heart Hospital, 16-18 Westmoreland Street, London W1M 8PH, UK; gopalamurugan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Valve-in-valve (VIV) implantation with the transcatheter aortic valve implantation (TAVI) technology has been used to treat dysfunctional bioprosthetic valves. A factor that determines a patient's suitability is the valve size of the previously implanted bioprosthetic valve. A 64-year-old lady with previous tricuspid valve replacement (33 mm stented tissue valve, model: ESP100-33M-00 Epic, St Jude Medical, Minnesota, USA), was referred for treatment of her dysfunctional tricuspid valve due to severe …

View Full Text


  • Contributors All the authors in this article contributed on the following: (1) conception and design, or analysis and interpretation of data, drafting the article, or revising it critically for important intellectual content; (2) final approval of the version to be published.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.